Ossium Health, Inc. a bioengineering company developing the world’s first bank of on-demand bone marrow, today announced a $52 million Series C funding round. The round was led by CPMG, with participation from Vivo Capital, First Round Capital, Manta Ray Ventures, Alumni Ventures, and Asahi Kasei. The company is improving the health, vitality, and longevity of human beings through bioengineering and will deploy this funding to dramatically grow its proprietary bone marrow bank, build on existing clinical trials, and accelerate new product development.
This round of funding will also support the launch of OssiGraft™, an orthopedic product for the repair, replacement, and reconstruction of musculoskeletal defects. This product is derived from the same vertebral bodies as Ossium’s other products, and provides another opportunity to honor the precious gift of donated tissue.
Read the full story here.
